This trial will test a new drug, ARV-471, to see if it is safe and effective at treating advanced breast cancer. The trial will also test if the new drug is more effective when used in combination with another drug, palbociclib.
6 Primary · 13 Secondary · Reporting Duration: through study completion, up to approximately 2 years
Experimental Treatment
215 Total Participants · 2 Treatment Groups
Primary Treatment: ARV-471 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: